These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30325701)

  • 1. Patient Reaction to Telemedicine for Clinical Management of Hepatitis C Virus Integrated into an Opioid Treatment Program.
    Talal AH; McLeod A; Andrews P; Nieves-McGrath H; Chen Y; Reynolds A; Sylvester C; Dickerson SS; Markatou M; Brown LS
    Telemed J E Health; 2019 Sep; 25(9):791-801. PubMed ID: 30325701
    [No Abstract]   [Full Text] [Related]  

  • 2. Care Integration for Hepatitis C Virus Treatment Through Facilitated Telemedicine Within Opioid Treatment Programs: Qualitative Study.
    Dickerson SS; George SJ; Ventuneac A; Dharia A; Talal AH
    J Med Internet Res; 2024 Jun; 26():e53049. PubMed ID: 38865703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated, Co-located, Telemedicine-based Treatment Approaches for Hepatitis C Virus Management in Opioid Use Disorder Patients on Methadone.
    Talal AH; Andrews P; Mcleod A; Chen Y; Sylvester C; Markatou M; Brown LS
    Clin Infect Dis; 2019 Jul; 69(2):323-331. PubMed ID: 30329042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-centered HCV care via telemedicine for individuals on medication for opioid use disorder: Telemedicine for Evaluation, Adherence and Medication for Hepatitis C (TEAM-C).
    Talal AH; Markatou M; Sofikitou EM; Brown LS; Perumalswami P; Dinani A; Tobin JN
    Contemp Clin Trials; 2022 Jan; 112():106632. PubMed ID: 34813962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated Hepatitis C-Opioid Use Disorder Care Through Facilitated Telemedicine: A Randomized Trial.
    Talal AH; Markatou M; Liu A; Perumalswami PV; Dinani AM; Tobin JN; Brown LS
    JAMA; 2024 Apr; 331(16):1369-1378. PubMed ID: 38568601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Satisfaction with Patient-Centered Telemedicine for Hepatitis C Virus Delivered to Substance Users: A Mixed-Methods Study.
    Talal AH; Sofikitou EM; Wang K; Dickerson S; Jaanimägi U; Markatou M
    Telemed J E Health; 2023 Mar; 29(3):395-407. PubMed ID: 35925809
    [No Abstract]   [Full Text] [Related]  

  • 7. Facilitating engagement of persons with opioid use disorder in treatment for hepatitis C virus infection via telemedicine: Stories of onsite case managers.
    Talal AH; Jaanimägi U; Davis K; Bailey J; Bauer BM; Dharia A; George S; McLeod A; Morton K; Nugent A; Zeremski M; Dinani A; Des Jarlais DC; Perumalswami PV; Tobin JN; Dickerson SS
    J Subst Abuse Treat; 2021 Aug; 127():108421. PubMed ID: 34134875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics and current clinical practices of opioid treatment programs in the United States.
    Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
    Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Take Charge, Get Cured": Pilot testing a targeted mHealth treatment decision support tool for methadone patients with hepatitis C virus for acceptability and promise of efficacy.
    Jessop AB; Bass SB; Brajuha J; Alhajji M; Burke M; Gashat MT; Wellington C; Ventriglia N; Coleman J; D'Avanzo P
    J Subst Abuse Treat; 2020 Feb; 109():23-33. PubMed ID: 31856947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Facilitated telemedicine for hepatitis C virus: Addressing challenges for improving health and life for people with opioid use disorder.
    Talal AH; Jaanimägi U; Dharia A; Dickerson SS
    Health Expect; 2023 Dec; 26(6):2594-2607. PubMed ID: 37641398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C in a Mobile Low-Threshold Methadone Program.
    Silva MJ; Pereira C; Loureiro R; Balsa C; Lopes P; Água-Doce I; Belo E; Martins HC; Coutinho R; Pádua E
    Eur J Gastroenterol Hepatol; 2017 Jun; 29(6):657-662. PubMed ID: 28151750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of social determinants of health and substance use characteristics on persons who use drugs pursuit of care for hepatitis C virus infection.
    Williams N; Bossert N; Chen Y; Jaanimägi U; Markatou M; Talal AH
    J Subst Abuse Treat; 2019 Jul; 102():33-39. PubMed ID: 31202286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
    Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program.
    Butner JL; Gupta N; Fabian C; Henry S; Shi JM; Tetrault JM
    J Subst Abuse Treat; 2017 Apr; 75():49-53. PubMed ID: 28237054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scaling and Sustaining Facilitated Telemedicine to Expand Treatment Access Among Underserved Populations: A Qualitative Study.
    Ventuneac A; Dickerson SS; Dharia A; George SJ; Talal AH
    Telemed J E Health; 2023 Dec; 29(12):1862-1869. PubMed ID: 37252770
    [No Abstract]   [Full Text] [Related]  

  • 16. Bridge clinic implementation of "72-hour rule" methadone for opioid withdrawal management: Impact on opioid treatment program linkage and retention in care.
    Taylor JL; Laks J; Christine PJ; Kehoe J; Evans J; Kim TW; Farrell NM; White CS; Weinstein ZM; Walley AY
    Drug Alcohol Depend; 2022 Jul; 236():109497. PubMed ID: 35607834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of methadone clinic staff attitudes toward hepatitis C evaluation and treatment.
    Talal AH; Dimova RB; Seewald R; Peterson RH; Zeremski M; Perlman DC; Des Jarlais DC
    J Subst Abuse Treat; 2013 Jan; 44(1):115-9. PubMed ID: 22405884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of an mHealth Intervention on Hepatitis C Testing Uptake Among People With Opioid Use Disorder: Randomized Controlled Trial.
    Hochstatter KR; Gustafson DH; Landucci G; Pe-Romashko K; Cody O; Maus A; Shah DV; Westergaard RP
    JMIR Mhealth Uhealth; 2021 Feb; 9(2):e23080. PubMed ID: 33616545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Examination of the Hepatitis C Virus care continuum among individuals with an opioid use disorder in substance use treatment.
    Brown JL; Gause NK; Lewis D; Winhusen T
    J Subst Abuse Treat; 2017 May; 76():77-80. PubMed ID: 28162850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Client and staff experiences of a co-located service for hepatitis C care in opioid substitution treatment settings in New South Wales, Australia.
    Treloar C; Rance J; Grebely J; Dore GJ
    Drug Alcohol Depend; 2013 Dec; 133(2):529-34. PubMed ID: 23932843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.